Expression Of ERCC1 And The Correlation With Platinum-based Chemotherapy Sensitivity And Clinical Significance In The Advanced Non-small Cell Lung Cancer

Objective: To investigate the expression of ERCC1 and the correlation with platinum-based chemotherapy sensitivity in advanced non-small cell lung cancer (NSCLC) as well as its clinical prognostic significance. Methods: The expression of ERCC1 was examined by immuno histoche-mical technique in 81 patients with advanced non-small cell lung cancer. All patientswere treated with platinum-based chemotherapy. Results: In these 81 cases,positive expression rates of ERCC1 was 38.5% (29/81), and there were no correlation with patient age, gender ,scor,clinical stage and smoking, but its expression in pulmonary adenocarcinoma was higher than that in squamous carcinoma. The response rate of of platinum-based chemotherapy in positive expression group was 20.69%, which in negative group was 55.77%, and there was significant difference between the two groups (P<0.05). The average survival time was 344 days in ERCC1 expression positive group,which was 537 days in ERCC1 expression negative group, survival analysis was carried by Kaplan-Meier analysis and there has significant difference (P<0.05). Conclusion: The expression of ERCC1 correlate with paltinum-based chemothempy sensitivity and could predict the sensitivity in advanced non-small cell lung cancer.Positive expression of ERCC1 predicates poor prognosis for patients with advanced NSCLC. The result of this study may provide new sight for tailor chemotherapy (TC) and decision prognosis to individual NSCLC patients.